Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan To Introduce New Quality Verification System For Generic Drugs

This article was originally published in PharmAsia News

Executive Summary

In an effort to reduce safety concerns about generic drugs and increase generic usage, Japan's Ministry of Health, Labor and Welfare will introduce a third-party verification system, in addition to the ministry's approval review. The new system will verify efficacy, and confirm that generics use the same active ingredients as brand products and contain no impure substances. MHLW has established a study group under the National Institute of Health Science to spearhead the system's implementation; the group's first meeting took place July 10. (Click here for more - Japanese language

You may also be interested in...



Japanese MHLW Lists 99 Generics For NHI Pricing And Coverage

TOKYO - Japan's Ministry of Health, Labor and Welfare Nov. 7 listed 99 generic drugs made from 35 composites for National Health Insurance price listing and coverage, according to an official of the ministry's Insurance Bureau Nov. 13

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel